• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?

作者信息

D'Amico Ferdinando, Peyrin-Biroulet Laurent, Danese Silvio

机构信息

Gastroenterology and Endoscopy, IRCCS Ospedale San Raffaele and Vita-Salute San Raffaele University, Milan, Italy.

Department of Biomedical Sciences, Humanitas University, Milan, Italy.

出版信息

United European Gastroenterol J. 2023 Oct;11(8):717-719. doi: 10.1002/ueg2.12436. Epub 2023 Jul 3.

DOI:10.1002/ueg2.12436
PMID:37401029
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10576599/
Abstract
摘要

相似文献

1
Disease clearance in ulcerative colitis: Is the ultimate therapeutic target?溃疡性结肠炎中的疾病清除：是最终的治疗目标吗？
United European Gastroenterol J. 2023 Oct;11(8):717-719. doi: 10.1002/ueg2.12436. Epub 2023 Jul 3.
2
Crohn's & Colitis Australia inflammatory bowel disease audit: measuring the quality of care in Australia.澳大利亚克罗恩病和结肠炎协会炎症性肠病审计：衡量澳大利亚的护理质量。
Intern Med J. 2019 Jul;49(7):859-866. doi: 10.1111/imj.14187.
3
Inflammatory Bowel Disease.炎症性肠病。
Prim Care. 2023 Sep;50(3):411-427. doi: 10.1016/j.pop.2023.03.009. Epub 2023 May 10.
4
Renal Manifestations in Inflammatory Bowel Disease: A Cohort Study During the Biologic Era.炎症性肠病的肾脏表现：生物制剂时代的队列研究。
Med Sci Monit. 2022 Jul 6;28:e936497. doi: 10.12659/MSM.936497.
5
Clinical presentation of Crohn's, ulcerative colitis, and indeterminate colitis: Symptoms, extraintestinal manifestations, and disease phenotypes.克罗恩病、溃疡性结肠炎和未定型结肠炎的临床表现：症状、肠外表现及疾病表型
Semin Pediatr Surg. 2017 Dec;26(6):349-355. doi: 10.1053/j.sempedsurg.2017.10.003. Epub 2017 Oct 5.
6
Identification and diagnosis of Crohn disease and ulcerative colitis in children.儿童克罗恩病和溃疡性结肠炎的识别与诊断
J Paediatr Child Health. 2020 Nov;56(11):1731-1734. doi: 10.1111/jpc.14925. Epub 2020 May 29.
7
Extra-intestinal manifestations of inflammatory bowel diseases.炎症性肠病的肠外表现。
Pharmacol Res. 2020 Nov;161:105206. doi: 10.1016/j.phrs.2020.105206. Epub 2020 Sep 28.
8
Cancer in Inflammatory Bowel Disease.炎症性肠病相关癌症。
Gastroenterol Clin North Am. 2022 Sep;51(3):649-666. doi: 10.1016/j.gtc.2022.05.003. Epub 2022 Aug 30.
9
[Inflammatory bowel disease: an overview].[炎症性肠病：概述]
Med Monatsschr Pharm. 2013 Nov;36(11):402-8; quiz 409.
10
Differentiating ulcerative colitis from Crohn disease in children and young adults: report of a working group of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the Crohn's and Colitis Foundation of America.儿童及青年溃疡性结肠炎与克罗恩病的鉴别：北美儿科胃肠病学、肝病学和营养学会及美国克罗恩病和结肠炎基金会工作组报告
J Pediatr Gastroenterol Nutr. 2007 May;44(5):653-74. doi: 10.1097/MPG.0b013e31805563f3.

引用本文的文献

1
Anemoside B4 alleviates ulcerative colitis by attenuating intestinal oxidative stress and NLRP3 inflammasome via activating aryl hydrocarbon receptor through remodeling the gut microbiome and metabolites.芍药苷B4通过重塑肠道微生物群和代谢产物激活芳烃受体，减轻肠道氧化应激和NLRP3炎性小体，从而缓解溃疡性结肠炎。
Redox Biol. 2025 Jun 28;85:103746. doi: 10.1016/j.redox.2025.103746.
2
Gut microbiota-derived butyrate mediates the anticolitic effect of indigo supplementation through regulating CD4 T cell differentiation.肠道微生物群衍生的丁酸盐通过调节CD4 T细胞分化介导靛蓝补充剂的抗结肠炎作用。
Imeta. 2025 Apr 19;4(3):e70040. doi: 10.1002/imt2.70040. eCollection 2025 Jun.
3
Disease Clearance in Ulcerative Colitis: A Narrative Review.溃疡性结肠炎的疾病清除：一项叙述性综述
United European Gastroenterol J. 2025 Jul;13(6):902-910. doi: 10.1002/ueg2.12714. Epub 2025 Apr 16.
4
Novel outcomes in inflammatory bowel disease.炎症性肠病的新成果。
J Crohns Colitis. 2025 Apr 4;19(4). doi: 10.1093/ecco-jcc/jjaf040.
5
Advancing Therapeutic Targets in IBD: Emerging Goals and Precision Medicine Approaches.炎症性肠病治疗靶点的进展：新出现的目标与精准医学方法
Pharmaceuticals (Basel). 2025 Jan 10;18(1):78. doi: 10.3390/ph18010078.
6
AI and endoscopy/histology in UC: the rise of machine.人工智能与溃疡性结肠炎中的内镜检查/组织学：机器的崛起
Therap Adv Gastroenterol. 2024 Oct 18;17:17562848241275294. doi: 10.1177/17562848241275294. eCollection 2024.
7
Kuicolong-yu enema decoction retains traditional Chinese medicine enema attenuates inflammatory response ulcerative colitis through TLR4/NF-κB signaling pathway.溃结龙榆灌肠方保留灌肠通过TLR4/NF-κB信号通路减轻溃疡性结肠炎的炎症反应。
World J Gastrointest Surg. 2024 Apr 27;16(4):1149-1154. doi: 10.4240/wjgs.v16.i4.1149.

本文引用的文献

1
Emerging drugs for the treatment of moderately to severely active ulcerative colitis: review of phase II and III clinical trials.治疗中重度溃疡性结肠炎的新兴药物：Ⅱ期和Ⅲ期临床试验综述。
Expert Opin Emerg Drugs. 2023 Mar;28(1):27-42. doi: 10.1080/14728214.2023.2186399. Epub 2023 Mar 7.
2
Going Beyond a Treat-To-Target to a Treat-To-Clear and a Treat-To-Trough Therapeutic Strategy in Patients with Inflammatory Bowel Disease?
J Crohns Colitis. 2023 Jun 16;17(6):825-826. doi: 10.1093/ecco-jcc/jjad014.
3
Efficacy and Safety of Dual Targeted Therapy for Partially or Non-responsive Inflammatory Bowel Disease: A Systematic Review of the Literature.双重靶向治疗部分或无应答炎症性肠病的疗效和安全性：文献系统评价。
Dig Dis Sci. 2023 Jun;68(6):2604-2623. doi: 10.1007/s10620-023-07837-0. Epub 2023 Feb 20.
4
Ulcerative colitis: Impact of early disease clearance on long-term outcomes - A multicenter cohort study.溃疡性结肠炎：早期疾病缓解对长期结局的影响-一项多中心队列研究。
United European Gastroenterol J. 2022 Sep;10(7):775-782. doi: 10.1002/ueg2.12288. Epub 2022 Sep 15.
5
Breaking Through the Therapeutic Ceiling: What Will It Take?突破治疗瓶颈：需要什么？
Gastroenterology. 2022 Apr;162(5):1507-1511. doi: 10.1053/j.gastro.2021.09.078. Epub 2022 Jan 4.
6
Bimekizumab versus Secukinumab in Plaque Psoriasis.比美吉珠单抗与司库奇尤单抗治疗斑块状银屑病的疗效比较。
N Engl J Med. 2021 Jul 8;385(2):142-152. doi: 10.1056/NEJMoa2102383. Epub 2021 Apr 23.
7
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD.STRIDE-II：炎症性肠病（STRIDE）国际研究组织（IOIBD）治疗靶点选择更新：确定炎症性肠病靶向治疗策略的治疗目标。
Gastroenterology. 2021 Apr;160(5):1570-1583. doi: 10.1053/j.gastro.2020.12.031. Epub 2021 Feb 19.
8
Transcriptional Signatures That Define Ulcerative Colitis in Remission.定义缓解期溃疡性结肠炎的转录特征。
Inflamm Bowel Dis. 2021 Jan 1;27(1):94-105. doi: 10.1093/ibd/izaa075.
9
Evolving therapeutic goals in ulcerative colitis: towards disease clearance.溃疡性结肠炎不断演变的治疗目标：迈向疾病清除。
Nat Rev Gastroenterol Hepatol. 2020 Jan;17(1):1-2. doi: 10.1038/s41575-019-0211-1.
10
Risankizumab compared with adalimumab in patients with moderate-to-severe plaque psoriasis (IMMvent): a randomised, double-blind, active-comparator-controlled phase 3 trial.利斯库珠单抗与阿达木单抗治疗中重度斑块型银屑病患者的疗效比较（IMMvent）：一项随机、双盲、活性对照的 3 期临床试验。
Lancet. 2019 Aug 17;394(10198):576-586. doi: 10.1016/S0140-6736(19)30952-3. Epub 2019 Jul 4.